C4 Therapeutics Income Statement (2019-2026) | CCCC

Income Statement Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
9.78M8.50M20.08M7.65M13.83M6.75M2.85M3.76M2.66M11.07M3.26M3.04M12.01M15.36M5.18M7.24M6.46M11.23M11.02M6.15M
Operating items
Amortization - Intangibles (Quarter)
Research & Development (Quarter)
23.29M24.30M26.55M26.20M31.32M29.66M30.65M29.04M29.93M28.35M30.39M22.53M23.75M31.84M32.51M27.07M26.20M25.99M24.98M24.61M
Selling, General & Administrative (Quarter)
8.61M8.45M8.78M12.82M9.89M9.58M10.49M10.95M10.31M10.53M10.30M10.29M9.70M11.77M10.37M9.33M8.77M8.92M9.18M9.33M
Other Operating Expenses (Quarter)
2.44M10.73M
Operating Expenses (Quarter)
31.90M32.75M35.33M39.02M41.22M39.24M41.15M39.99M40.23M38.88M40.69M35.26M33.45M43.61M42.89M36.40M34.96M45.64M34.16M33.94M
Operating Income (Quarter)
-22.12M-24.25M-15.26M-31.37M-27.38M-32.49M-38.29M-36.23M-37.57M-27.81M-37.43M-32.22M-21.44M-28.24M-37.71M-29.16M-28.50M-34.41M-23.14M-27.79M
EBIT (Quarter)
-22.12M-24.25M-15.26M-31.37M-27.38M-32.49M-38.29M-36.23M-37.57M-27.81M-37.43M-32.22M-21.44M-28.24M-37.71M-29.16M-28.50M-34.41M-23.14M-27.79M
Non-operating items
Non Operating Investment Income (Quarter)
0.03M-0.09M-0.62M-2.88M-0.93M-0.83M1.27M1.67M0.70M0.87M0.78M-0.25M-0.06M0.90M-0.40M-0.01M-0.07M
Interest & Investment Income (Quarter)
0.07M0.11M0.14M0.28M0.51M1.08M1.71M2.05M2.25M2.56M2.95M3.86M3.73M3.58M3.27M2.84M2.48M2.25M2.78M2.66M
Other Non Operating Income (Quarter)
-0.62M
Non Operating Income (Quarter)
-0.46M-0.43M-0.40M-0.25M-0.03M0.53M1.11M1.45M1.65M1.77M2.95M3.86M3.73M3.58M3.27M2.84M2.48M2.25M2.78M2.66M
Net income details
EBT (Quarter)
-22.58M-24.68M-15.66M-31.62M-26.88M-31.96M-37.19M-34.78M-35.92M-26.03M-34.48M-28.36M-17.72M-24.67M-34.44M-26.32M-26.02M-32.17M-20.36M-25.13M
Tax Provisions (Quarter)
1.00M0.28M0.13M
Profit After Tax (Quarter)
-22.58M-24.68M-15.67M-31.62M-27.41M-31.96M-37.19M-34.78M-35.92M-27.04M-34.75M-28.36M-17.72M-24.67M-34.57M-26.32M-26.02M-32.17M-20.49M-25.13M
Income from Continuing Operations (Quarter)
-22.58M-24.68M-15.66M-31.62M-26.88M-31.96M-37.19M-34.78M-35.92M-27.04M-34.76M-28.36M-17.72M-24.67M-34.57M-26.32M-26.02M-32.17M-20.36M-25.13M
Consolidated Net Income (Quarter)
-22.58M-24.68M-15.66M-31.62M-26.88M-31.96M-37.19M-34.78M-35.92M-27.04M-34.76M-28.36M-17.72M-24.67M-34.57M-26.32M-26.02M-32.17M-20.36M-25.13M
Income towards Parent Company (Quarter)
-22.58M-24.68M-15.66M-31.62M-26.88M-31.96M-37.19M-34.78M-35.92M-27.04M-34.76M-28.36M-17.72M-24.67M-34.57M-26.32M-26.02M-32.17M-20.36M-25.13M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
-22.58M-24.68M-15.66M-31.62M-26.88M-31.96M-37.19M-34.78M-35.92M-27.04M-34.76M-28.36M-17.72M-24.67M-34.57M-26.32M-26.02M-32.17M-20.36M-25.13M
Additional items
EPS (Basic) (Quarter)
-0.51-0.51-0.31-0.65-0.56-0.65-0.76-0.71-0.73-0.55-0.68-0.41-0.26-0.35-0.49-0.37-0.37-0.44-0.09-0.20
EPS (Weighted Average and Diluted) (Quarter)
-0.51-0.51-0.31-0.65-0.56-0.65-0.76-0.71-0.73-0.55-0.68-0.41-0.26-0.35-0.49-0.37-0.37-0.44-0.09-0.20
Shares Outstanding (Weighted Average) (Quarter)
43.47M45.16M46.04M48.73M48.82M48.92M48.86M49.03M49.06M49.21M49.64M68.43M68.62M69.63M69.37M70.83M71.01M72.56M28.71M126.07M
Shares Outstanding (Diluted Average) (Quarter)
43.86M45.16M46.04M48.73M48.82M48.92M48.86M49.03M49.05M49.10M49.64M68.43M68.81M68.96M69.37M70.83M71.01M72.56M82.89M126.07M
EBITDA (Quarter)
-22.55M-24.77M-16.28M-34.49M-28.34M-32.79M-35.91M-33.11M-35.23M-26.17M-33.98M-28.61M-17.78M-23.77M-34.98M-26.33M-26.09M-32.05M-20.58M-25.50M
Tax Rate (Quarter)
-3.85%-0.81%-0.38%